Could an antibody finally treat long COVID?
NCT ID NCT05877508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single dose of the monoclonal antibody AER002 can safely improve physical health in adults with Long COVID. The idea is that lingering virus or spike protein may cause ongoing symptoms, and the antibody might clear it. 36 participants will receive either AER002 or a placebo, and their physical health will be measured using a standard questionnaire at 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AER002 (a monoclonal antibody)
What this could lead to
If it works, this could point toward a treatment for Long COVID by targeting lingering virus or spike protein.
What could go wrong
This is a small, early-phase trial with only 36 people, so results may not apply broadly. The antibody only works against certain virus variants, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF/Zuckerberg San Francisco General Hospital
San Francisco, California, 94110, United States